Gottlieb, McClellan: Incentivize Use Of RWE To Back COVID-19 Therapies

By Beth Wang / May 22, 2020 at 1:16 PM
In a Wednesday (May 20) report, former FDA chiefs Mark McClellan and Scott Gottlieb call for increased funding and incentives to encourage collection and use of real-world evidence for COVID-19 therapies that make it to market through Emergency Use Authorization or FDA approval. RWE will play a major role in filling key evidence gaps and answering questions about cost effectiveness that might exist for marketed COVID-19 therapies, especially those that come to market through emergency authorization before trials are complete,...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.